Literature DB >> 28609761

Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Sho Hasegawa1, Noritoshi Kobayashi, Motohiko Tokuhisa, Ayumu Goto, Shoko Takano, Yuuki Takada, Tomohiro Kaneta, Ryutaro Mori, Ryusei Matsuyama, Itaru Endo, Shoji Yamanaka, Atsushi Nakajima, Tomio Inoue, Yasushi Ichikawa.   

Abstract

BACKGROUND/AIMS: Somatostatin receptor (SSTR) scintigraphy (SRS) is the standard imaging modality for evaluation of gastroenteropancreatic neuroendocrine tumor (GEP-NET) in Western countries. However, this modality was not approved in Japan until recently. The purpose of this study was to evaluate the clinical efficacy of SRS for detecting GEP-NET in Japanese patients.
METHODS: Japanese patients with advanced GEP-NET were enrolled and evaluated by the SRS and CT. We also compared SRS and immunohistochemical expression of SSTR type 2a (SSTR2a).
RESULTS: We enrolled 16 patients and the primary sites were the pancreas in 9, the stomach in 1, the small intestine in 2, the colon in 3, and unknown in 1. SRS showed positive findings in 3 (100%) of grade 1 (G1) and in 12 (92.3%) of grade 2 (G2) lesions. In the liver, SRS and CT detected lesions in 13 and 14 cases, respectively. The concordance rate of SSTR2a expression with SRS findings was 93.8% in the whole body and 92.9% in the liver.
CONCLUSIONS: SRS could detect almost all of G1 and G2. SRS could be useful to detect lesions, with a high concordance rate with CT and pathological findings. We confirmed that SRS is a useful and reliable modality for Japanese patients.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  111In-pentetreotide; Gastroenteropancreatic neuroendocrine tumor; Immunohistochemistry; Neuroendocrine tumor; SRS (111In-octreotide somatostatin receptor scintigraphy); Somatostatin receptor scintigraphy

Mesh:

Substances:

Year:  2017        PMID: 28609761     DOI: 10.1159/000470838

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells.

Authors:  Yanhua Zhao; Lin Peng; Xiang Li; Yi Zhang
Journal:  Exp Ther Med       Date:  2018-09-12       Impact factor: 2.447

2.  Usefulness of selective arterial calcium injection tests for functional pancreatic neuroendocrine tumors.

Authors:  Yutaka Nakano; Minoru Kitago; Masahiro Shinoda; Seishi Nakatsuka; Isao Kurihara; Hiroshi Yagi; Yuta Abe; Go Oshima; Shutaro Hori; Takahiro Yokose; Yuko Kitagawa
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

3.  Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms.

Authors:  Yoshitaka Inaba; Susumu Hijioka; Isanori Iwama; Tsubasa Asai; Hiroki Miyamura; Shohei Chatani; Takaaki Hasegawa; Shinichi Murata; Mina Kato; Yozo Sato; Hidekazu Yamaura; Hiroaki Onaya; Junichi Shimizu; Kazuo Hara
Journal:  Asia Ocean J Nucl Med Biol       Date:  2022

4.  Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours.

Authors:  Moritz Jesinghaus; Jelte Poppinga; Bettina Lehman; Elisabeth Maurer; Annette Ramaswamy; Albert Grass; Pietro Di Fazio; Anja Rinke; Carsten Denkert; Detlef K Bartsch
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

5.  Primary hepatic neuroendocrine neoplasm diagnosed by somatostatin receptor scintigraphy: A case report.

Authors:  Miho Akabane; Yuta Kobayashi; Keiichi Kinowaki; Satoshi Okubo; Junichi Shindoh; Masaji Hashimoto
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.